Market Newsdesk

SANTA ANA, Calif., May 09, 2025 (GLOBE NEWSWIRE) — TTM Technologies, Inc. (NASDAQ:TTMI) today announced that its Board of Directors authorized a new share repurchase program allowing the Company to repurchase its outstanding common stock with an aggregate market value of up to $100 million from time to time through May 7, 2027. The Company’s previous two-year repurchase program expired on May 3, 2025.

“Given the company’s solid cash flow generation and strong balance sheet, we believe repurchasing shares is a prudent use of capital,” said Dan Boehle, Executive Vice President and Chief Financial Officer. “While strategic acquisitions remain a primary goal for the use of our free cash flow, this authorization provides us with added flexibility to enhance shareholder value.”

The timing, manner, price and amount of any share repurchases will be determined by the Company’s management based on various factors, such as available liquidity, cash flows and general market conditions. The repurchase program may be executed through open market purchases, privately negotiated transactions and other methods, including through Rule 10b5-1 plans. The authorization does not obligate the Company to acquire any particular amount of common stock and the program may be suspended or discontinued at the Company’s discretion without prior notice.

About TTM

TTM Technologies, Inc. is a leading global manufacturer of technology solutions, including mission systems, radio frequency (“RF”) components, RF microwave/microelectronic assemblies, and quick-turn and technologically advanced printed circuit boards (“PCB”s). TTM stands for time-to-market, representing how TTM’s time-critical, one-stop design, engineering and manufacturing services enable customers to reduce the time required to develop new products and bring them to market. Additional information can be found at www.ttm.com.

Forward Looking Statements

This release contains forward-looking statements that relate to future events or performance. TTM cautions you that such statements are simply predictions and actual events or results may differ materially. These statements reflect TTM’s current expectations, and TTM does not undertake to update or revise these forward looking statements, even if experience or future changes make it clear that any projected results expressed or implied in this or other TTM statements will not be realized. Further, these statements involve risks and uncertainties, many of which are beyond TTM’s control, which could cause actual results to differ materially from the forward-looking statements. These risks and uncertainties include, but are not limited to, general market and economic conditions, including interest rates, currency exchange rates and consumer spending, demand for TTM’s products, market pressures on prices of TTM’s products, warranty claims, changes in product mix, contemplated significant capital expenditures and related financing requirements, TTM’s dependence upon a small number of customers and other factors set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s public reports filed with the SEC.

Contact:
Sameer Desai,
Senior Director, Corporate Development & Investor Relations
[email protected]
714-327-3050

New York, May 09, 2025 (GLOBE NEWSWIRE) — Skycorp Solar Group Limited (Nasdaq: PN) (“Skycorp” or “the Company”), a solar PV product provider engaged in the manufacture and sale of solar cables and solar connectors, marked its Nasdaq debut by ringing the Opening Bell, signaling a transformation phase in its mission to accelerate renewable energy adoption worldwide. The achievement also coincides with the Company’s plan to localize operation in the United States as Skycorp gears up to set up local team to drive growth in this high-growth market.

“We are in a process to set up a subsidiary in the United States to seize growth opportunities offered by this burgeoning market where the installed capacity is expected to double to 375 GW by 2030 (SEIA, 2024),” said Mr. Weiqi Huang, Chief Executive Officer of the Company. “Today in the U.S., nearly 7% of the electricity already comes from solar energy, which is more than seven times that of ten years ago (SEIA, 2024). So Skycorp’s Nasdaq listing provides critical capital to help us localize operations in the country,” said Mr. Huang.

“Skycorp also looks to form strategic partnerships with U.S. financial institutions to co-develop integrated solar-storage-charging projects and establish local teams to better support commercial and industrial clients and spearhead market research tailored for the U.S. market,” Mr. Huang added.

Years of Innovation: From Startup to Nasdaq

Founded in 2011 with the vision of “benefiting all human being with solar,” Skycorp has over the years become a leading provider of solar cables and connectors. The Company’s patented fire-retardant solar cables and ultra-durable waterproof connectors, which follow European International Electrotechnical Commission and TÜV production standards, serve clients across 30+ countries, while boasting a 90% customer retention rate.

Future-Focused Initiatives

Skycorp in its prospectus unveiled plans to launch smart junction boxes and intelligent solar charging stations for EVs by late 2025, designed to simplify renewable energy integration for consumers and enterprises.

“The U.S. market is critical to our global strategy,” Mr. Huang continued, “By localizing innovation, we also aim to make Skycorp synonymous with affordable, American-made solar solutions.”

About Skycorp Solar Group Limited

Skycorp Solar Group Limited is a solar photovoltaic (PV) product provider focused on manufacturing and selling solar cables and connectors. Our operations are managed through our subsidiaries, including Ningbo Skycorp Solar Co., Ltd., in China.

The Company’s mission is to become a green energy solutions provider by utilizing solar power and delivering eco-friendly solar PV products. By leveraging the Company’s expertise in solar technologies and relationships with worldwide clients, it aims to expand offerings of solar PV products and energy solutions for enterprise customers. For more information, please visit: https://ir.skycorp.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Skycorp Solar Group Limited
Cathy
Investor Relations
Email: [email protected]
Tel: +86 185 0252 9641 (CN)

WFS Investor Relations Inc.
Connie Kang
Partner
Email: [email protected]
Tel: +86 1381 185 7742 (CN)

–  This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease

–  RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review

LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV-GAD for the treatment of Parkinson’s disease not adequately controlled with anti-Parkinsonian medications.

This RMAT was awarded following the presentation to the FDA of positive data from 3 clinical studies demonstrating the benefit of AAV-GAD when administered in a one-time stereotactic infusion to the subthalamic nucleus in the brain. A Phase 1 dose escalating clinical study (n=12) was conducted, followed by a double-blind, sham-controlled Phase 2 study (n=45) and a second randomized, double-blind, sham-controlled dose ranging clinical bridging study (n=14).

“We are very pleased to have been awarded this RMAT designation for our AAV-GAD product in Parkinson’s disease,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “The data from our double-blind, sham-controlled Phase 2 studies show significant clinically meaningful benefit on the standard motor endpoint in Parkinson’s disease, UPDRS Part 3, as well as other validated measures of Parkinson’s symptoms. What is most exciting is the analysis of the data from these Phase 2 studies using the AI technology of our partner Hologen. Through the use of Hologen’s technology applied to the data from our double-blind, sham-controlled studies, we have demonstrated disease modifying changes in the circuitry of the brain of patients treated with AAV-GAD as well as potentially protective changes in the substantia nigra and regions of the brain involved in cognition and mood. This is the first time sham-controlled gene or cell therapy Phase 2 studies have shown significant benefit in UPDRS and now, to our knowledge, the only demonstration of disease modification in a sham or placebo-controlled study in Parkinson’s disease.”

Dr. Forbes continued, “We are excited to have been granted RMAT designation for our AAV-GAD program in Parkinson’s disease and we look forward to working closely with the FDA to bring this potential life changing therapy to this large population of Parkinson’s patients in need of effective and disease modifying treatments for this serious neurodegenerative disorder.”

The requirements for receiving an RMAT designation include that the drug candidate is an advanced regenerative medicine, in this case a gene therapy; that the therapy is targeting a serious condition, in this case, Parkinson’s disease; and that the applicant has presented clinical evidence demonstrating that the drug candidate has the potential to address an unmet need in the serious condition. The RMAT requirement for clinical data supporting a benefit in an unmet need is a high hurdle, with less than half of all RMAT designation applications granted.

The RMAT designation is aimed to expedite the development and review of promising Regenerative Medicine therapeutic candidates, including human gene therapies, that treat, modify, reverse or cure serious or life-threatening diseases. Similar to Breakthrough Therapy designation, RMAT designation allows for increased interaction with the FDA and immediate multidisciplinary comprehensive discussions of the ongoing product development program, clinical trials and plans for expediting the manufacturing development strategy. RMAT designation includes the benefits of Fast Track and Breakthrough Therapy designations with rolling review and potential Priority Review of a product’s biologics license application (BLA).

About AAV-GAD

Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s, with nearly one million people in the U.S. currently living with Parkinson’s disease and approximately 90,000 new patients diagnosed annually in the U.S. There are more than 10 million people worldwide currently living with PD. Most individuals with PD initially respond to dopamine replacement therapy, yet for a large percentage of patients, over time, this type of treatment is no longer sufficiently helpful while adverse effects of medication can also occur, leading to a considerable reduction in quality of life and the ability to function effectively. The cause of Parkinson’s disease is unknown for a majority of patients, while a much smaller percentage have a known genetic cause, but in all cases, there is dysfunction of the key circuits that control movement. AAV-GAD is an investigational gene therapy designed to reprogram these dysfunctional brain circuits through the local production of GABA, a chemical neurotransmitter that can help restore more normal activity to these critical cells in any form of PD. AAV-GAD is delivered via a one-time infusion through a minimally invasive procedure, using a MeiraGTx proprietary device that allows infusion of the equivalent of one drop of gene therapy solution into the subthalamic nucleus, a key regulator of the circuits responsible for normal movement.

About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-stage clinical programs. Each of these programs use local delivery of small doses resulting in disease modifying effects in both inherited and more common diseases, in the eye, Parkinson’s disease and radiation-induced xerostomia. MeiraGTx uses its innovative technology in optimization of capsids, promoters and novel translational control elements to develop best in class, potent, safe viral vectors. MeiraGTx’s broad pipeline is supported by end-to-end in-house manufacturing. MeiraGTx has built the most comprehensive manufacturing capabilities in the industry, with 5 facilities globally, including two that are licensed for GMP viral vector production and a GMP QC facility with clinical and commercial licensure. In addition, MeiraGTx has developed a proprietary manufacturing platform process over 9 years based on more than 20 different viral vectors with leading yield and quality aspects and commercial readiness. Uniquely, MeiraGTx has developed a novel technology for in vivo delivery of any biologic therapeutic using oral small molecules. This transformative riboswitch gene regulation technology allows precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on the regulated in vivo delivery of metabolic peptides, including GLP-1, GIP, Glucagon, Amylin, PYY and Leptin, as well as cell therapy, CAR-T for liquid and solid tumors and autoimmune diseases, and additionally PNS targets addressing long term intractable pain. MeiraGTx has developed the technology to apply genetic medicine to common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.

For more information, please visit www.meiragtx.com

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our product candidate development and anticipated milestones regarding our pre-clinical and clinical data, reporting of such data and the timing of results of data and regulatory matters, statements regarding the collaboration with Hologen, including the anticipated timing for its closing and funding thereunder, the success of the activities to be performed under the collaboration, the efficacy of Hologen’s AI technology, the development of our AAV-GAD and other CNS product candidates and the development of our manufacturing technology, as well as statements that include the words “expect,” “will,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “could,” “should,” “would,” “continue,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, our incurrence of significant losses; any inability to achieve or maintain profitability, raise additional capital, repay our debt obligations, identify additional and develop existing product candidates, successfully execute strategic transactions or priorities, bring product candidates to market, expansion of our manufacturing facilities and processes, successfully enroll patients in and complete clinical trials, accurately predict growth assumptions, recognize benefits of any orphan drug or rare pediatric disease designations, retain key personnel or attract qualified employees, or incur expected levels of operating expenses; the impact of pandemics, epidemics or outbreaks of infectious diseases on the status, enrollment, timing and results of our clinical trials and on our business, results of operations and financial condition; failure of early data to predict eventual outcomes; failure to obtain FDA or other regulatory approval for product candidates within expected time frames or at all; the novel nature and impact of negative public opinion of gene therapy; failure to comply with ongoing regulatory obligations; contamination or shortage of raw materials or other manufacturing issues; changes in healthcare laws; risks associated with our international operations; significant competition in the pharmaceutical and biotechnology industries; dependence on third parties; risks related to intellectual property; changes in tax policy or treatment; our ability to utilize our loss and tax credit carryforwards; litigation risks; and the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts

Investors:
MeiraGTx
[email protected]

or

Media:
Jason Braco, Ph.D.
LifeSci Communications
[email protected]

DALLAS, May 09, 2025 (GLOBE NEWSWIRE) — Westwood Holdings Group (NYSE: WHG) (“Westwood”), a publicly traded investment management boutique, trust and wealth services firm, is pleased to announce that Randy A. Bowman has been elected as the new Chairman of its Board of Directors.

Randy succeeds Dick Frank who served as a Westwood board member for 19 years, was Westwood’s Board Chair for the last 10 years of his service and will be stepping down as a member following his many years of dedicated service to Westwood.

“Dick’s contributions to Westwood have been invaluable,” said Brian O. Casey, Westwood’s Chief Executive Officer. “His steady leadership and deep commitment to our mission have left a lasting imprint on the firm. On behalf of the entire Westwood family, we extend our sincere gratitude to Dick for his years of service and guidance.”

A member of Westwood’s board since 2021, Randy Bowman brings a wealth of experience as an entrepreneur, innovator, leader and philanthropist. His leadership roles include Chair of the City of Dallas Employee Retirement Fund and the Impact Dallas Capital Mezzanine Fund. Over the past four years, Randy has played an active role in shaping Westwood’s strategic direction and is well-positioned to build on the leadership legacy established by founder Susan Byrne and Dick Frank.

“I am honored to be entrusted with this role at this exciting and pivotal juncture of Westwood’s journey,” said Mr. Bowman. “I look forward to working with my fellow Board members, Brian and the entire Westwood team as we continue executing our strategy and creating long-term value for our shareholders.”

Casey added, “We are very pleased to have Randy lead our Board. With his background as an accomplished entrepreneur, fund allocator and investor in the betterment of Dallas, Randy is able to provide important leadership and support for Westwood.”

Contact:
Sheana Suek
(214) 756-6900
[email protected]

ABOUT WESTWOOD HOLDINGS GROUP, INC.

Westwood Holdings Group, Inc. (NYSE: WHG) is a boutique asset management firm that offers a diverse array of actively-managed and outcome-oriented investment strategies, along with white-glove trust and wealth services, to institutional, intermediary and private wealth clients. For over 40 years, Westwood’s client-first approach has fostered strong, long-term client relationships due to our unwavering commitment to delivering bespoke investment strategies with a vehicle-optimized approach, exceptional counsel and unparalleled client service. Our flexible and agile approach to investing allows us to adapt to constantly changing markets, while continually seeking innovative strategies that meet our investors’ short and long-term needs.

Our team at Westwood comes from varied backgrounds and life experiences, which reflects our origins as a woman-founded firm. We are committed to incorporating diverse insights and knowledge into all aspects of our services and solutions. Our culture and approach to our business reflect our core values—integrity, reliability, responsiveness, adaptability, flexibility and collaboration—and underpin our constant pursuit of excellence. For more information on Westwood, please visit westwoodgroup.com​.

ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3^rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET.

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics

Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information: 
Investors:  
Alina Venezia 
[email protected]
(734) 887-3903 

Media:  
Tiffany Aldrich  
[email protected]
(616) 443-8438 

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) — Fiverr International Ltd, (NYSE: FVRR), the company that is changing how the world works together, today announced that Micha Kaufman, Founder and Chief Executive Officer, and Ofer Katz, President and Chief Financial Officer, will present at the upcoming J.P. Morgan Global Technology, Media and Communications Conference:

J.P. Morgan Global Technology, Media and Communications Conference

Date: Tuesday, May 13, 2025
Time: 3:50 pm Eastern Time

A live webcast of the presentation will be accessible from the Events & Presentations section of Fiverr’s investor relations website, https://investors.fiverr.com. An archived replay of the audio webcast will be available following the live presentation from the same website.

About Fiverr

Fiverr’s mission is to transform the way the world creates and works together. We’re shaping the future of work with the world’s leading open platform, seamlessly connecting top talent and cutting-edge technology with businesses around the globe. From expert freelancers in over 750 skilled categories to best-in-class GenAI models and agents, Fiverr provides the most advanced and comprehensive talent and tools for digital services—helping businesses get mission-critical projects done fast and cost-effectively.

From small businesses to Fortune 500 companies, millions trust Fiverr for projects in software and AI development, digital marketing, finance, business consulting, video animation, music, architecture, and more.

Learn how to future-proof your business with exceptional talent and cutting-edge tools at fiverr.com. Follow us on LinkedIn, Instagram, TikTok, and Facebook.

Investor Relations:
Jinjin Qian
[email protected]

Press:
Jenny Chang
[email protected]

Source: Fiverr International Ltd.